Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
IFRX InflaRx N.V. daily Stock Chart
IFRX [NASD]
InflaRx N.V.
Healthcare | Biotechnology | Germany
financial highlights | statements
Index- P/E- EPS (ttm)-1.44 Insider Own44.16% Shs Outstand25.24M Perf Week-2.90%
Market Cap760.99M Forward P/E- EPS next Y-2.15 Insider Trans- Shs Float14.13M Perf Month-10.27%
Income-35.50M PEG- EPS next Q-0.42 Inst Own44.70% Short Float1.75% Perf Quarter-13.24%
Sales- P/S- EPS this Y-166.60% Inst Trans0.28% Short Ratio10.98 Perf Half Y4.47%
Book/sh5.10 P/B5.91 EPS next Y-34.00% ROA-33.30% Target Price44.02 Perf Year-
Cash/sh5.26 P/C5.73 EPS next 5Y- ROE-59.60% 52W Range14.47 - 42.83 Perf YTD43.91%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-29.61% Beta-
Dividend %- Quick Ratio27.70 Sales past 5Y- Gross Margin- 52W Low108.36% ATR2.38
Employees21 Current Ratio27.70 Sales Q/Q- Oper. Margin- RSI (14)45.36 Volatility7.42% 7.36%
OptionableNo Debt/Eq0.00 EPS Q/Q-151.50% Profit Margin- Rel Volume0.37 Prev Close30.29
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume22.48K Price30.15
Recom1.80 SMA20-3.65% SMA50-5.80% SMA2006.12% Volume8,357 Change-0.46%
Jul-13-18Initiated BMO Capital Markets Outperform $45
Jun-28-18Initiated SunTrust Buy $55
Jun-28-18Initiated Raymond James Outperform
Feb-08-18Initiated B. Riley FBR, Inc. Buy $40
Aug-09-18 07:00AM  InflaRx N.V. Reports Second Quarter 2018 Financial & Operating Results GlobeNewswire
Jun-28-18 07:30AM  InflaRx Receives IND Approval from the FDA to Start its Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis GlobeNewswire
Jun-05-18 07:30AM  InflaRx Opens New Research Facility in Ann Arbor GlobeNewswire
May-17-18 07:30AM  InflaRx N.V. Reports First Quarter 2018 Financial & Operating Results GlobeNewswire
May-08-18 10:42AM  InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shares GlobeNewswire
May-03-18 08:28PM  InflaRx N.V. Announces Pricing of Primary and Secondary Offering of Common Shares GlobeNewswire -7.05%
May-02-18 07:44AM  InflaRx N.V. Announces Proposed Primary and Secondary Offerings of Common Shares GlobeNewswire -6.54%
Mar-29-18 07:00AM  InflaRx Full Year 2017 Financial & Operating Results GlobeNewswire
Mar-12-18 08:40AM  Blog Exposure - InflaRx Enrolled First Patient in Phase-IIb Trial of Lead Candidate IFX-1 in Hidradenitis Suppurativa ACCESSWIRE +7.98%
Mar-08-18 08:23AM  InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa Business Wire
Feb-06-18 07:52AM  InflaRx Announces Appointment of Tony Gibney to Its Board of Directors Business Wire
Feb-01-18 09:55AM  InflaRx Presents at Two Scientific Conferences in February, 2018 Business Wire
Jan-23-18 01:53PM  Breaking Down InflaRx NVs (NASDAQ:IFRX) Ownership Structure Simply Wall St.
Jan-15-18 10:51AM  What Can We Expect for InflaRx NV (NASDAQ:IFRX) Moving Forward? Simply Wall St.
Jan-09-18 08:56AM  InflaRx receives IND acceptance to proceed with a Phase IIb Trial with lead candidate IFX-1 in Hidradenitis Suppurativa Business Wire
Jan-04-18 01:47PM  InflaRx to Present at Upcoming Investor Conferences Business Wire +13.56%
08:00AM  InflaRx NV (NASDAQ:IFRX): Are Analysts Bull Or Bear? Simply Wall St.
Nov-10-17 08:05AM  The Biotech IPO Boom Will Continue, Nasdaq Execs Predict Forbes
Nov-08-17 01:31PM  InflaRX NV (Nasdaq: IFRX) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
open in yahoo | open in reuters | open in google